Get the Stockscreener App
1.62
6.90%
-0.12
Tscan Therapeutics Inc stock is traded at $1.62, with a volume of 462.38K.
It is down -6.90% in the last 24 hours and up +13.29% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.74
Open:
$1.7
24h Volume:
462.38K
Relative Volume:
0.83
Market Cap:
$84.75M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.905
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-16.06%
1M Performance:
+13.29%
6M Performance:
-36.96%
1Y Performance:
-76.28%
1-Day Range:
$1.6021
$1.7677
1-Week Range:
$1.6021
$1.99
52-Week Range:
$1.02
$6.81
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
880 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.62 | 98.47M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Can TScan Therapeutics Inc. rally from current levelsAsset Allocation Summary With Future Outlook - Newser
Order flow analysis tools used on TScan Therapeutics Inc.Fundamental Analysis for Value Stock Selection - Newser
What is the dividend policy of TScan Therapeutics Inc. stockFree Stock Ideas For Smart Trading - jammulinksnews.com
Should you hold or exit TScan Therapeutics Inc. nowEntry Zone Watchlist With Momentum Focus - Newser
What recovery options are there for TScan Therapeutics Inc.Free Price Action Based Buy Opportunity List - Newser
TScan Therapeutics Inc. stock trend forecastTechnical Trend Forecast for Investors - Newser
Visualizing TScan Therapeutics Inc. stock with heatmapsShort Term Gain Strategy with AI Logic - Newser
Measuring TScan Therapeutics Inc.’s beta against major indicesFree Strong Buy With Technical Confidence - Newser
TScan Therapeutics, Inc. Trade Ideas — BOATS:TCRX - TradingView
When is TScan Therapeutics Inc. stock expected to show significant growthMarket Forecast Opportunities For Every Investor - jammulinksnews.com
What machine learning models say about TScan Therapeutics Inc.Free AI Driven Buy Alert Trade Blueprint - Newser
Real time alert setup for TScan Therapeutics Inc. performanceExit Ready Momentum Stock Watchlist Expanded - metal.it
Intrinsic Value of TScan Therapeutics Inc. Stock: Is It Undervalued or OvervaluedEntry Optimization Guide with Volume Analysis - Newser
How TScan Therapeutics Inc. stock performs during market volatilityFree Scalable Portfolio Growth Suggestions - Newser
Candlestick signals on TScan Therapeutics Inc. stock todayIntraday Price Action Forecast Planner - Newser
TScan Therapeutics Inc. stock outlook for YEARRisk/Reward Optimization Entry Point Analysis - Newser
Evaluating TScan Therapeutics Inc. with trendline analysisFree Short Term Setup With Predictive Chart - Newser
Fibonacci Support Holding Strong in TScan Therapeutics Inc.Short Term Trading Opportunity Watch Sees Shift - metal.it
Trendlines Suggest TScan Therapeutics Inc. May Bottom Out SoonReliable Alerts for Daily Stock Movers Released - metal.it
TScan Therapeutics Inc. Stock Support and Resistance Levels You Should KnowWeekly Stock Market Strategy Summary - Newser
Published on: 2025-07-29 09:01:11 - metal.it
What makes TScan Therapeutics Inc. stock price move sharplyTrack top-performing stocks in real-time - jammulinksnews.com
How strong is TScan Therapeutics Inc. company’s balance sheetBuild a diversified portfolio for sustainable growth - jammulinksnews.com
Why TScan Therapeutics Inc. stock attracts strong analyst attention AI Screener for Daily Stock Forecast - Newser
What are the latest earnings results for TScan Therapeutics Inc.Build a diversified portfolio for stability - jammulinksnews.com
How many analysts rate TScan Therapeutics Inc. as a “Buy”Achieve breakthrough performance with smart picks - jammulinksnews.com
How does TScan Therapeutics Inc. compare to its industry peersDiscover undervalued opportunities early - jammulinksnews.com
New Product Launches: Will They Boost TScan Therapeutics Inc. Stock in 2025Free Professional Trading Signals - metal.it
TScan Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Trading Group - Newser
TScan Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveBreakout Setup Scanner - Newser
TScan Therapeutics Inc. Stock Analysis and ForecastBreakthrough stock performance - PrintWeekIndia
Why TScan Therapeutics Inc. stock attracts strong analyst attentionAI-Based Signal Detection for Active Traders - Newser
Does TScan Therapeutics Inc. stock pay reliable dividendsDynamic capital growth - jammulinksnews.com
How high can TScan Therapeutics Inc. stock price go in 2025Game-changing returns - jammulinksnews.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):